Bart Westerman

Abstract Astrocytomas and oligodendrogliomas are isocitrate dehydrogenase (IDH)-mutant gliomas that most commonly arise in adults under the age of 50 and exhibit variable responses to treatment1,2,3. To understand the genetic drivers of disease progression, here we used whole-genome and whole-exome sequencing to characterize longitudinally collected tumour specimens from 183 patients with IDH-mutant glioma. Samples were collected through the Glioma Longitudinal Analysis (GLASS) Consortium4.

arising from R. S. Narayan et al. Nature Communications https://doi.org/10.1038/s41467-020-16735-2 (2020) Synergistic drug interactions can be assessed in a laboratory setting by multiple methods that do not necessarily lead to the same outcome; hence, the optimal way to determine synergy is a matter of an ongoing debate.

Abstract The evolutionary processes that drive malignant progression of IDH-mutant astrocytomas remain unclear. Here, we performed multiomics on matched initial and recurrent tumor samples from a cohort of 105 patients and overlaid the data with detailed clinical annotation. We identified overlapping features associated with malignant progression that are derived from three molecular mechanisms: cell cycling, tumor cell (de)differentiation and remodeling of the extracellular matrix.